HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Induction of Connective Tissue Growth Factor Expression by Hypoxia in Human Lung Fibroblasts via the MEKK1/MEK1/ERK1/GLI-1/GLI-2 and AP-1 Pathways.

Abstract
Several reports have indicated that hypoxia, GLI, and connective tissue growth factor (CTGF) contribute to pulmonary fibrosis in idiopathic pulmonary fibrosis. We investigated the participation of mitogen-activated protein kinase kinase (MEK) kinase 1 (MEKK1)/MEK1/ERK1/GLI-1/2 and activator protein-1 (AP-1) signaling in hypoxia-induced CTGF expression in human lung fibroblasts. Hypoxia time-dependently increased CTGF expression, which was attenuated by the small interfering RNA (siRNA) of GLI-1 (GLI-1 siRNA) and GLI-2 (GLI-2 siRNA) in both human lung fibroblast cell line (WI-38) and primary human lung fibroblasts (NHLFs). Moreover, GLI-1 siRNA and GLI-2 siRNA attenuated hypoxia-induced CTGF-luciferase activity, and the treatment of cells with hypoxia induced GLI-1 and GLI-2 translocation. Furthermore, hypoxia-induced CTGF expression was reduced by an MEK inhibitor (PD98059), MEK1 siRNA, ERK inhibitor (U0126), ERK1 siRNA, and MEKK1 siRNA. Both PD98059 and U0126 significantly attenuated hypoxia-induced CTGF-luciferase activity. Hypoxia time-dependently increased MEKK1, ERK, and p38 MAPK phosphorylation. Moreover, SB203580 (a p38 MAPK inhibitor) also apparently inhibited hypoxia-induced CTGF expression. The treatment of cells with hypoxia induced ERK, GLI-1, or GLI-2 complex formation. Hypoxia-induced GLI-1 and GLI-2 translocation into the nucleus was significantly attenuated by U0126. In addition, hypoxia-induced ERK Tyr204 phosphorylation was impeded by MEKK1 siRNA. Moreover, hypoxia-induced CTGF-luciferase activity was attenuated by cells transfected with AP-1 site mutation in a CTGF construct. Exposure to hypoxia caused a time-dependent phosphorylation of c-Jun, but not of c-Fos. Chromatin immunoprecipitation (ChIP) revealed that hypoxia induced the recruitment of c-Jun, GLI-1, and GLI-2 to the AP-1 promoter region of CTGF. Hypoxia-treated cells exhibited an increase in α-smooth muscle actin (α-SMA) and collagen production, which was blocked by GLI-1 siRNA and GLI-2 siRNA. Overall, these data implied that the MEKK1/MEK1/ERK1/GLI-1/GLI-2, and AP-1 pathways mediated hypoxia-induced CTGF expression in human lung fibroblasts. Furthermore, GLI-1 and GLI-2 found to be involved in hypoxia-induced α-SMA and collagen expression.
AuthorsYi Cheng, Chien-Huang Lin, Jing-Yun Chen, Chien-Hua Li, Yu-Tin Liu, Bing-Chang Chen
JournalPloS one (PLoS One) Vol. 11 Issue 8 Pg. e0160593 ( 2016) ISSN: 1932-6203 [Electronic] United States
PMID27486656 (Publication Type: Journal Article)
Chemical References
  • CCN2 protein, human
  • GLI1 protein, human
  • GLI2 protein, human
  • Kruppel-Like Transcription Factors
  • Nuclear Proteins
  • Transcription Factor AP-1
  • Zinc Finger Protein GLI1
  • Zinc Finger Protein Gli2
  • Connective Tissue Growth Factor
  • Mitogen-Activated Protein Kinase 3
  • MAP Kinase Kinase Kinase 1
  • MAP3K1 protein, human
  • MAP Kinase Kinase 1
  • MAP2K1 protein, human
Topics
  • Cells, Cultured
  • Connective Tissue Growth Factor (genetics, metabolism)
  • Fibroblasts (metabolism)
  • Humans
  • Hypoxia (genetics, metabolism)
  • Kruppel-Like Transcription Factors (genetics, metabolism)
  • Lung (metabolism)
  • MAP Kinase Kinase 1 (metabolism)
  • MAP Kinase Kinase Kinase 1 (metabolism)
  • MAP Kinase Signaling System (genetics, physiology)
  • Mitogen-Activated Protein Kinase 3 (metabolism)
  • Nuclear Proteins (genetics, metabolism)
  • Primary Cell Culture
  • Pulmonary Fibrosis (genetics, metabolism, pathology)
  • Transcription Factor AP-1 (metabolism)
  • Zinc Finger Protein GLI1 (genetics, metabolism)
  • Zinc Finger Protein Gli2

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: